MedTrace Logo

Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fasting Condition

NCT01827865 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2013-04-10

No results posted yet for this study

Summary

This is a open Label, balanced, randomized, single dose, two-treatment, two-sequence, two-period, crossover, oral pivotal bioequivalence study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fasting condition in healthy, adult human subjects.

Conditions

  • Fasting

Interventions

DRUG

Etodolac Extended Release Tablets USP 600mg

Etodolac Extended Release Tablets USP 600mg once a day

DRUG

Etodolac Extended Release Tablets 600mg

Etodolac Extended Release Tablets 600mg once a day

Sponsors & Collaborators

  • IPCA Laboratories Ltd.

    lead INDUSTRY

Principal Investigators

  • Dr. Hardik Dave, M.B.B.S · Veeda Clinical Research Pvt. Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01827865 on ClinicalTrials.gov